Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Germline mutation in the RAD51B gene confers predisposition to breast cancer

Lisa Golmard12*, Virginie Caux-Moncoutier1, Grégoire Davy1, Essam Al Ageeli1, Brigitte Poirot1, Carole Tirapo1, Dorothée Michaux1, Catherine Barbaroux1, Catherine Dubois d’Enghien1, André Nicolas1, Laurent Castéra1, Xavier Sastre-Garau1, Marc-Henri Stern12, Claude Houdayer123 and Dominique Stoppa-Lyonnet123

Author Affiliations

1 Institut Curie, Department of Tumour Biology, 26 rue d’Ulm, 75248, Paris, Cedex 05, France

2 Institut Curie, INSERM U830, 26 rue d’Ulm, 75248, Paris, Cedex 05, France

3 Université Paris Descartes, Sorbonne Paris Cité, 12 rue de l’école de Médecine, 75270 Paris, Cedex 06, France

For all author emails, please log on.

BMC Cancer 2013, 13:484  doi:10.1186/1471-2407-13-484

Published: 19 October 2013

Abstract

Background

Most currently known breast cancer predisposition genes play a role in DNA repair by homologous recombination. Recent studies conducted on RAD51 paralogs, involved in the same DNA repair pathway, have identified rare germline mutations conferring breast and/or ovarian cancer predisposition in the RAD51C, RAD51D and XRCC2 genes. The present study analysed the five RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3) to estimate their contribution to breast and ovarian cancer predisposition.

Methods

The study was conducted on 142 unrelated patients with breast and/or ovarian cancer either with early onset or with a breast/ovarian cancer family history. Patients were referred to a French family cancer clinic and had been previously tested negative for a BRCA1/2 mutation. Coding sequences of the five genes were analysed by EMMA (Enhanced Mismatch Mutation Analysis). Detected variants were characterized by Sanger sequencing analysis.

Results

Three splicing mutations and two likely deleterious missense variants were identified: RAD51B c.452 + 3A > G, RAD51C c.706-2A > G, RAD51C c.1026 + 5_1026 + 7del, RAD51B c.475C > T/p.Arg159Cys and XRCC3 c.448C > T/p.Arg150Cys. No RAD51D and XRCC2 gene mutations were detected. These mutations and variants were detected in families with both breast and ovarian cancers, except for the RAD51B c.475C > T/p.Arg159Cys variant that occurred in a family with 3 breast cancer cases.

Conclusions

This study identified the first RAD51B mutation in a breast and ovarian cancer family and is the first report of XRCC3 mutation analysis in breast and ovarian cancer. It confirms that RAD51 paralog mutations confer breast and ovarian cancer predisposition and are rare events. In view of the low frequency of RAD51 paralog mutations, international collaboration of family cancer clinics will be required to more accurately estimate their penetrance and establish clinical guidelines in carrier individuals.

Keywords:
Genetic predisposition; Breast cancer; Ovarian cancer; RAD51 paralogs; RAD51B